Delcath Systems Inc (DCTH) News

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver...

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver...

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 8-K - Current report

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Fourth Quarter Revenue Approximately $15.1 Million and Full Year Total Revenue Approximately $37.2 Million Delcath Systems, Inc. (Nasdaq: DCTH...

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and...